MSC-Based Therapies for COVID-19 (October 2020 update)

At the beginning of August, we searched the clinicaltrials.gov database to learn more about the U.S.-based clinical trial landscape of mesenchymal stromal cell (MSC) based therapies for COVID-19. The original search, conducted on July 31, 2020, revealed an active landscape filled with 53 “active” clinical trials (i.e., Available; Recruiting; Active, not recruiting; Enrolling by invitation). For […]

MSC-Based Therapies for COVID-19

MSC-Based Therapies for COVID-19: Current Clinical Trial Landscape Data Mesenchymal stem/stromal cells (MSCs) are emerging as a potential treatment modality for COVID-191-3. MSCs have immunomodulatory properties that can be used to combat the inflammatory response caused by the SARS-CoV-2 coronavirus, and the United States Food and Drug Administration (FDA) has granted accelerated approvals to several […]